An interventional study of Extracorporeal Shock Wave Therapy and Hyaluronic Acid (HA) in Chronic Patellar Tendinopathy, sponsored by Chang Gung Memorial Hospital. Active, not recruiting at 1 site in Taiwan. Open to participants aged 15 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-09-15.
Sponsored by Chang Gung Memorial Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing platelet rich plasma in Tendinopathy — 2 open to participants now, 4 under way, none of them phase 3. platelet rich plasma · Tendinopathy.
Among the 14 studies testing platelet rich plasma in Tendinopathy, this one is the 9th largest by planned enrollment, is the only one that started in 2026, is one of 4 with no phase, and was the 14th registered.
397 studies on the registry are indexed under Tendinopathy; 77 are open to participants now.
Browse Tendinopathy studies →2 of the 14 studies testing platelet rich plasma in Tendinopathy are open now, in 2 countries. Recruiting first, the newest first:
University of Utah · Sites in United States
Ages 18+ · Healthy volunteers
Mahidol University · Sites in Thailand
Ages 18–70
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 47 Tendinopathy studies recruiting now, 17 (36%) set no upper age limit and 23 (49%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.
This study: 15 Years to 40 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 45 is close to the median of 48 across 332 interventional studies indexed under Tendinopathy.
Median enrollment 62 across the 14 interventional studies. Of the 7 that completed or were terminated, 3 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 14 has an industry lead sponsor. The 10 most frequent:
Chang Gung Memorial Hospital is the lead sponsor of 1,098 studies on the registry; 241 are open to participants now.
Chang Gung Memorial Hospital has 2 studies filed under Tendinopathy — fewer than ten, so there is no comparison to draw.
2 of the studies testing platelet rich plasma in Tendinopathy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05603468Second Affiliated Hospital, School of Medicine, Zhejiang UniversityEffect of PRP vs Corticosteroid in Rotator Cuff Tendinopathy Subtypes in Arthroscopic Repair | 2026-12-31 |
| NCT07819968Chang Gung Memorial HospitalChronic Patellar Tendinopathy (PT)is Prevalent in Participants of Several Sports.A Three-arm, Single-blind Randomized Controlled Trial Will be Conducted. We Want to Compare the Clinical Effectiveness of ESWT Alone, ESWT Combined With Hyaluronic Acid, and ESWT Combined With PRP in Athletes With PT | 2027-07-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies testing platelet rich plasma in Tendinopathy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Chronic patellar tendinopathy is highly prevalent among youth, amateur, and elite athletes, with rates reaching 30-40% in high-performance populations. Among current conservative treatments, platelet-rich plasma (PRP) injections and extracorporeal shockwave therapy (ESWT) have demonstrated promising clinical outcomes. However, high-quality randomized controlled trials comparing ESWT alone versus ESWT combined with different injection therapies remain lacking.
Objective:
To compare the clinical effectiveness of ESWT alone, ESWT combined with hyaluronic acid (HA), and ESWT combined with PRP in athletes with chronic patellar tendinopathy.
Methods:
A three-arm, single-blind randomized controlled trial will be conducted. Athletes participating in sports with repetitive jumping or explosive lower-limb loading will be enrolled and stratified by sport type. Inclusion criteria include typical anterior knee pain, a positive decline squat test, and ultrasonographic evidence of tendon thickening or hypoechoic changes. Calcified tendinopathy will be excluded.
Outcomes will be assessed at 1, 3, 6, 9, and 12 months, including VAS, VISA-P, SPORTS scale, sport-specific performance tests (vertical jump, single-leg hop, agility tests), and return-to-play (RTP) time.
Expected Impact:
This study aims to address three key clinical questions:
1. Research Objective: Chronic patellar tendinitis is a common and highly recurrent sports injury among advanced athletes. Currently, various non-surgical treatments, such as ESWT and PRP injections, are commonly used clinically. However, high-quality randomized controlled trials are lacking regarding whether combined injection therapy is necessary and whether ESWT combined with HA or PRP is more suitable for athletes. This study aims to comprehensively compare the efficacy of ESWT alone versus ESWT combined with either injection therapy through three parallel, stratified, randomized, single-blind clinical trials, providing clinically applicable treatment guidelines.
The objectives of this study are:
2. Research Hypotheses:
3. Study Endpoints
4. Study Design
This study is a prospective clinical trial with three parallel, stratified, randomized, single-blind (subject-blind) groups. The study aimed to compare the clinical efficacy, functional recovery, and return to play (RTP) differences between:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Typical positive results on physical examination (at least two of the following must be positive):
Positive Decline squat test Single-leg decline squat pain ≥3/10 Palpation tenderness over patellar tendon (tenderness ≥3/10) Pain induced by Hop test / drop jump
Patellar tendon thickness >4.0 mm or thicker than the healthy side by ≥15% Hypoechoic area Disorganized fibers Doppler grade 1-2 neovascularity (5) Able to cooperate with research tracking and functional testing
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This group served as the control group in the experimental design, receiving only shockwave therapy. Saline was administered only for the purpose of a single-blind trial.
Device: Extracorporeal Shock Wave Therapy · Other: Normal Saline
deliver a gel-like fluid directly into the joint to lubricate cartilage and relieve osteoarthritis pain when basic treatments fail. Hyaluronic acid combined with shockwave therapy aims to achieve effects beyond pain relief.
Device: Extracorporeal Shock Wave Therapy · Drug: Hyaluronic Acid (HA)
A platelet-rich plasma (PRP) injection is a treatment that uses a high concentration of your own blood platelets to help heal injured joints, tendons, and muscles. The combination of PRP and shockwave therapy is expected to achieve results exceeding those of either treatment alone.
Device: Extracorporeal Shock Wave Therapy · Biological: Platelet-Rich Plasma
Shockwave therapy is a treatment method that uses high-energy sound waves delivered to body tissues. Through shockwave stimulation of specific frequencies and energy levels, it acts on areas of pain or dysfunction, promoting tissue repair. It is commonly used for chronic musculoskeletal discomfort and sports injury-related problems. In this program, shockwave therapy is the basic treatment, and each experimental group will receiveExtracorporeal Shock Wave Therapy (
Hyaluronic acid is primarily used in medicine as an intra-articular injection to relieve pain from osteoarthritis and lubricate joints.
PRP (Platelet-Rich Plasma) Brief Introduction and Definition: Concentrated blood plasma rich in platelets and growth factors, extracted from the patient's own blood. Uses: Belonging to regenerative medicine and proliferative therapy, it is commonly used to help repair soft tissues such as muscles, tendons, ligaments, and joints. Principle: Utilizing growth factors from the patient's own blood, it accelerates the healing and regeneration of body tissues.
Normal saline is a 0.9% sterile aqueous solution of sodium chloride. Its osmotic pressure is similar to that of human blood plasma, and it is widely used in medical and daily care. In this study, it was used as a placebo.
Visual Analogue Scale(VAS)
VAS(Visual Analogue Scale):Ask the patient to mark the degree of their pain on a 10 cm line, from "no pain" on the far left to "unbearable pain" on the far right. The "Numerical Rating Scale" uses a numerical concept of 0-10 points to express the degree of pain, from no pain (0 points) to very painful (10 points).
Time frame: From enrollment to the end of treatment at 48 weeks
The Victorian Institute of Sport Assessment (VISA-) Patella (P) Questionnaire
VISA-P: A professional self-assessment tool used to evaluate the severity and treatment effectiveness of patellar tendinopathy. The maximum score is 100 points. A higher score indicates milder symptoms and better function; a lower score indicates a more severe condition. Question Structure: Contains 8 questions. First 6 questions: Assess the degree of pain and functional limitations in specific daily activities (such as sitting, squatting, climbing stairs, hopping on one leg, etc.). Last 2 questions: Assess the level of motor engagement, the ability to train, and the duration of training.
Time frame: From enrollment to the end of treatment at 48 weeks
SPORTS score (Subjective Patient Outcome for Return to Sports)
In the fields of sports medicine and orthopedics, the SPORTS scale (Subjective Patient Outcome for Return to Sports score) is a core assessment scale specifically designed to evaluate an athlete's ability to return to sports (RTS) after experiencing a sports injury (such as anterior cruciate ligament rupture, shoulder instability, elbow injury, etc.) and undergoing surgery or treatment. It comprises three independent conceptual constructs: 1) the ability to return to pre-injury intensity and training levels; 2) the ability to achieve the same level of athletic performance; and 3) the ability to achieve 1) and 2 above without pain or with pain relief. This tool uses a 10-point scale, where 0 indicates the patient cannot return to their pre-injury level of athletic performance, and 10 indicates the patient can perform the same sport with the same effort and performance level as before the injury without pain
Time frame: From enrollment to the end of treatment at 48 weeks
Return to Play (RTP)
Return to Play (RTP) refers to the complete decision-making process by which athletes safely and gradually return to training and competition after injury or surgery, through medical treatment, physical therapy, and scientific training. RTP comprises three main phases: Return to Participation: Begin non-contact, basic physical and technical rehabilitation training. Return to Sport: Participate in sport-specific movements, simulated competition, and team training. Return to Performance: Recover to the pre-injury competitive level and peak performance.
Time frame: From enrollment to the end of treatment at 48 weeks
Ultrasound Assessment: Joint Effusion
Measurement of joint effusion in the knee joint using ultrasound examination. Unit of Measure: millimeter(mm)
Time frame: From enrollment to the end of treatment at 48 weeks
Ultrasound Assessment: Medial Meniscus (MM) Extrusions Width at Full Extension
Measurement of medial meniscus extrusion width at full extension using ultrasound examination.Unit of Measure: millimeter(mm)
Time frame: From enrollment to the end of treatment at 48 weeks
Ultrasound Assessment: Medial Meniscus (MM) Extrusion Width at Standing Weight-Bearing
Measurement of medial meniscus extrusion width during standing weight-bearing using ultrasound examination.Unit of Measure: millimeter(mm)
Time frame: From enrollment to the end of treatment at 48 weeks
Ultrasound Assessment: Medial Collateral Ligament (MCL) Thickness at Full Extension
Measurement of medial collateral ligament thickness at full extension using ultrasound examination.Unit of Measure: millimeter(mm)
Time frame: From enrollment to the end of treatment at 48 weeks
Ultrasound Assessment: Doppler Signal at Medial Meniscus (MM) Body
Assessment of vascularization and inflammation via Doppler ultrasound signal at the medial meniscus body.
Time frame: Unit of Measure: (Semi-quantitative scale, 0-3)
Started Sep 2026 (actual). Primary completion is estimated for Jul 2027, 10 months after the start.
Of 173 non-industry interventional studies with no phase under Tendinopathy, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's planned 10 months is below that.
Counting every sponsor, half of 182 studies reached it within 20 months; a quarter within 7 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Hyaluronic Acid · Platelet rich plasma
Chang Gung Memorial Hospital →